Q-omics provides the consensus-scored CUX1 profile across patient tissues and cancer cell-line models. CUX1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CUX1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CUX1 protein abundance shows 22,726 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, HNSC, and GBM as cancer lineages where CUX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CUX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CUX1 survival associations across molecular data types. CUX1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CUX1 RNA expression–survival associations across cancer types. High CUX1 expression shows unfavorable associations in COAD, UVM, CESC and ACC, but favorable associations in KIRC and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CUX1 RNA expression.
This table summarizes CUX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CUX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CUX1 shows lower tumor expression in THCA, BLCA and UCEC and higher tumor expression in HNSC, LIHC and KIRP. The HNSC box plot shows higher CUX1 RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with CUX1 in patient tissues and cancer cell lines. In patient samples, CUX1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CUX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
